Lumateperone and Paliperidone interaction
Lumateperone and Paliperidone: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Lumateperone (CAPLYTA) label · effective 2025-06-20
Agranulocytosis (including fatal cases) has been reported with other antipsychotic drugs.
Seizures Like other antipsychotic drugs, CAPLYTA may cause seizures.
Potential for Cognitive and Motor Impairment CAPLYTA, like other antipsychotics, may cause somnolence and has the potential to impair judgment, thinking, and motor skills.
From the Paliperidone (Erzofri extended-release) label · effective 2026-03-09
ERZOFRI and other antipsychotic drugs should be used cautiously in patients at risk for aspiration.
Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.
Like other antipsychotic drugs, ERZOFRI should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.